FAPI PET在乳腺癌中的诊断性能:系统综述
该系统综述纳入13项研究,评估FAPI PET在乳腺癌诊断及新辅助化疗免疫治疗(NAC)后疗效评估中的诊断性能。FAPI PET较[18F]FDG PET在所有解剖部位检测到更多病灶,NAC后评估乳腺肿瘤的灵敏度和特异度分别为73%-100%和71%-100%。低级别、Luminal A型及小叶组织学肿瘤的FAPI摄取较低。
要点
- FAPI PET在乳腺癌原发灶、腋窝淋巴结及远处转移灶检测中均优于[18F]FDG PET。
- NAC后FAPI PET评估乳腺肿瘤的灵敏度73%-100%,特异度71%-100%。
- 低级别、Luminal A型及小叶癌的FAPI摄取较低。
核心结论
- FAPI PET在乳腺癌诊断时较[18F]FDG PET检测到更多病灶,并在NAC后疗效评估中表现出可观的诊断性能。
研究设计与样本
- 系统检索PubMed、EMBASE、Web of Science和Cochrane Trial数据库至2026年1月12日,最终纳入13项研究。
- 采用QUADAS-2工具评估研究质量,提取SUVmax、靶本比及病灶检测数据。
主要发现
- 原发肿瘤FAPI PET与[18F]FDG PET的SUVmax范围分别为6.5-17.1和3.9-8.3。
- 腋窝淋巴结转移灶SUVmax范围分别为5.1-17.1和1.2-10.3。
- 远处转移灶SUVmax范围分别为4.9-21.7和1.7-8.1。
- FAPI PET在所有评估解剖部位均较[18F]FDG PET检测到更多病灶。
- NAC后评估乳腺肿瘤,FAPI PET灵敏度73%-100%、特异度71%-100%。
关键数值与推荐
- 10项研究比较FAPI PET与[18F]FDG PET,3项比较FAPI PET与NAC后组织病理学。
- 诊断性能参数(灵敏度73%-100%、特异度71%-100%)来自NAC后与组织病理学对照的研究。
临床怎么用
- FAPI PET可用于乳腺癌原发灶、淋巴结及远处转移的检测,并可能用于NAC后疗效评估。
- 对低级别、Luminal A型或小叶癌患者,需注意FAPI摄取可能较低。
局限性
- 纳入研究数量较少(13项),其中仅3项将FAPI PET与NAC后组织病理学进行对照。
- SUVmax等数据以范围形式报告,未提供汇总的合并诊断准确性估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the diagnostic performance of fibroblast activation protein inhibitor (FAPI) PET for lesion detection at breast cancer diagnosis and response assessment after neoadjuvant chemoimmunotherapy (NAC) and compared these findings with those from [18F]FDG PET or histopathology after the completion of NAC. Methods: A systematic search across PubMed, EMBASE, Web of Science, and Cochrane Trial databases up to January 12, 2026, was conducted. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies version 2 tool. Extracted data included SUVmax, tumor-to-background ratio, and lesion detection in studies comparing FAPI PET with [18F]FDG PET. For studies comparing FAPI PET with histopathology, diagnostic performance parameters were obtained. Data on FAPI uptake, stratified by histology type, molecular subtype, and tumor grade, were extracted. Results: The literature search yielded 3662 studies, 13 of which were included in this review. Of these, 10 compared FAPI PET with [18F]FDG PET and 3 compared FAPI PET findings with those of histopathology after the completion of NAC. The reported mean SUVmax range was 6.5-17.1 versus 3.9-8.3 for primary tumors, 5.1-17.1 versus 1.2-10.3 for axillary lymph node metastases, and 4.9-21.7 versus 1.7-8.1 for distant metastases on FAPI PET versus [18F]FDG PET, respectively. FAPI PET detected more lesions compared with [18F]FDG PET in all evaluated anatomic sites. In post-NAC response assessment of the breast tumor, FAPI PET reported a sensitivity and specificity of 73%-100% and 71%-100%, respectively. Lower FAPI uptake was observed in low-grade, luminal A tumors and in those with lobular histology. Conclusion: FAPI PET demonstrated increased lesion detection compared with [18F]FDG PET at the time of breast cancer diagnosis and demonstrated considerable diagnostic performance for assessing response evaluation after NAC.
引用
- Duijx LEHW, Lenaerts M, Smidt ML, et al. Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review. J Nucl Med. 2026. PMID: 42134978. doi:10.2967/jnumed.126.272191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。